A stock's price target isn't just a number, it's a claim about where a company is headed and why. 24/7 Wall St's Price Targets desk publishes our own price projections for individual stocks, built from company fundamentals, growth drivers, and risk factors, alongside real-time tracking of Wall Street analyst price target changes, upgrades, and downgrades. We show you both what the Street thinks and what we think, so you can judge a stock's path for yourself.
The Price Targets desk runs on two tracks. First, we build our own price projections for individual stocks using company fundamentals, growth catalysts, competitive position, and downside risks, laid out in bull, base, and bear scenarios. Second, we track Wall Street analyst price target changes as they happen, flagging upgrades, downgrades, and the reasoning behind them. Our goal is not to hand you a number, but to show you the case behind it, so you can decide how much weight it deserves.
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could reshape…
Credo Technology just posted its seventh consecutive quarter of triple-digit revenue growth, yet analysts still set targets well below where this volatile stock has already traded. One specific milestone in its optical business could…
Every major AI chip runs through one company's fabs, and its stock still trades cheaper than the customers that depend on it. Here is why analysts keep raising their targets despite a geopolitical sword…
Synopsys just surged to lead the Nasdaq 100 after a blockbuster Investor Day packed with OpenAI partnerships, Amazon deals, and a raised earnings outlook. Whether this rally has real staying power or faces serious…
Adobe beat earnings for the fifth straight quarter, yet the stock sits 31% in the hole for the year while a generative AI rival just torched its retail sentiment. Something has to give, and…
Tesla's FSD subscriptions are surging, Robotaxi is hitting the streets, and Optimus robots are coming off production lines, yet the stock sits 22% in the red for the year. Here is what bulls and…
Broadcom's AI revenue exploded 221% last quarter yet the stock sits nearly flat for the year, while Marvell and SanDisk have already handed investors life-changing gains. Here is whether all three can push even…
AMD has surged dramatically over the past year, and its AI ambitions stretch into trillion-dollar markets by 2030, but the model scoring it a hold at near fair value tells a more complicated story…
Broadcom, Marvell, and Oracle have gone in completely opposite directions in 2026, yet analysts see a path where all three deliver the same outsized result in 2027. Here is why the worst performer of…
Broadcom designs chips for Google, Meta, and OpenAI, beats earnings quarter after quarter, and still trades at a discount to the broader market. Here is the specific scenario where all of that adds up…
Marvell Technology has already surged over 200% this year, yet analysts keep piling on buy ratings and management is forecasting explosive custom chip growth through 2028. Whether that momentum can survive rising margin pressure…
Meta's ad engine is firing on all cylinders, yet a single line item in its budget has the power to flip bullish momentum into a costly trap for investors who ignore it.
Palantir just posted numbers that left Wall Street scrambling to justify its own cautious price targets, and the real question is whether the valuation ceiling everyone keeps citing is about to become a floor.
CoreWeave carries a backlog that dwarfs its closest rival and revenue growth that towers over legacy cloud giants, yet the stock still trades far below its 52-week high. Here is why the tension between…
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from…
